
- Teva Pharmaceutical (TEVA) is trading at new 5-year highs.
- Shares are up more than 40% over the past year.
- The stock has strong technical momentum, maintaining a 100% “Buy” opinion from Barchart.
- TEVA offers international diversification and is favored by both Wall Street and individual investors.